SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford GlycoSciences Plc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject1/17/2003 3:36:02 AM
From: nigel bates  Read Replies (1) of 469
 
OXFORD, England, Jan. 17 /PRNewswire-FirstCall/ -- Oxford GlycoSciences Plc (Nasdaq: OGSI - News; LSE: OGS - News) announced that an application for approval of Zavesca for the treatment of type 1 Gaucher disease has been submitted in Israel. A decision from the Israeli Ministry of Health is expected in six to nine months.

The application was filed by Teva Pharmaceutical Industries Ltd., who, under the terms of a license agreement with OGS, is responsible for all regulatory and marketing activities in Israel.

Zavesca is the first oral treatment for this disease. It was approved in the EU in November 2002 for the treatment of patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. (Full prescribing information in the English language is available at www.ogs.com.)

David Ebsworth, Ph.D., CEO of OGS said, "This filing is an important step in our plan to make Zavesca available in all major markets, as Israel has the second largest patient population for Gaucher disease. Zavesca offers physicians a needed addition to their therapeutic options for treating patients with this serious disease. We look forward to the commercial launch of Zavesca in key European markets and Israel during 2003."...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News